Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Assets: 2016-2025

Historic Non-Current Assets for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $16.5 million.

  • UroGen Pharma's Non-Current Assets rose 141.02% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 141.02%. This contributed to the annual value of $9.6 million for FY2024, which is 4.94% up from last year.
  • As of Q3 2025, UroGen Pharma's Non-Current Assets stood at $16.5 million, which was up 39.25% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Non-Current Assets peaked at $17.0 million during Q1 2023, and registered a low of $2.9 million during Q2 2024.
  • Over the past 3 years, UroGen Pharma's median Non-Current Assets value was $10.4 million (recorded in 2025), while the average stood at $10.3 million.
  • Per our database at Business Quant, UroGen Pharma's Non-Current Assets tumbled by 90.39% in 2021 and then surged by 311.28% in 2025.
  • Over the past 5 years, UroGen Pharma's Non-Current Assets (Quarterly) stood at $5.4 million in 2021, then rose by 25.32% to $6.7 million in 2022, then spiked by 35.95% to $9.1 million in 2023, then climbed by 4.94% to $9.6 million in 2024, then spiked by 141.02% to $16.5 million in 2025.
  • Its Non-Current Assets was $16.5 million in Q3 2025, compared to $11.8 million in Q2 2025 and $10.4 million in Q1 2025.